Navigation Links
Potential Cure for Lymphoma in HIV patients

Stem cell transplants have become the standard of care for patients with relapsed lymphoma, but not for patients who suffer from both this disease and HIV. A new study showing that this treatment is a viable option for select patients with HIV-associated lymphoma will be published in the January 15, 2005, issue of Blood, the official journal of the American Society of Hematology. Because of the immunodeficiency associated with HIV, HIV-positive patients are more likely to develop lymphoma than HIV-negative individuals, and the treatment for their cancer is far less likely to be successful.

Sonali Smith, M.D., Assistant Professor of Medicine at the University of Chicago notes, "The treatment of malignant lymphomas in HIV-infected individuals remains challenging, due to both the high incidence of refractory disease and the high risk of treatment-related complications. The ability of high dose chemotherapy as demonstrated in this pilot study to effectively treat even refractory disease is highly encouraging and certainly warrants further study." Researchers from the City of Hope Cancer Center studied 20 patients (aged 11 to 68) who had HIV and lymphoma, either Hodgkin’s or non-Hodgkin’s. The selected patients had undergone previous standard-dose frontline chemotherapy for their lymphoma, but the majority either failed to achieve a complete remission or had relapsed after an initial remission. The median length of study follow-up was approximately two and a half years, with a range of about six months to six years. All study patients were to undergo autologous stem cell rescue. In an autologous transplant, stem cells are removed from the patient and frozen for later use. The patient receives high-dose chemotherapy to kill any lymphoma in the body, and the autologous stem cells are then infused back into the patient to repopulate the bone marrow wiped out by the chemotherapy. Before the transplant, patients were given one of two conditioning regimens, either high dose chemotherapy alone or in combination with radiation therapy, to destroy the cancerous cells. Most (17 patients versus three) received the chemotherapy-only option. Radiation therapy was selected for patients younger than 55 who had poorer prognostic factors: either the cancer had spread to multiple lymph nodes or the patient had bulky disease (indicated by a cancerous mass greater than 5 ?10 cm). Reversible abnormalities in liver function, a side effect of the intensive treatment, were experienced in a majority of the patients. One patient, the oldest in the study, developed cardiomyopathy (a weakening of the heart) and kidney failure due to treatment toxicities and died a few weeks after the transplant. Opportunistic infections, such as herpes zoster and cytomegalovirus infection, also occurred in a few patients after the transplant, but were managed with appropriate therapy. Throughout the study, all patients were to receive highly active antiretroviral therapy (HAART) to help reduce these opportunistic infections and improve immunodeficiency, however, only nine patients were able to tolerate this treatment for the entire study due to side effects such as nausea and inflammation of the mouth lining. The majority of patients, though, did resume the HAART therapy soon after discharge from the hospital. Although two patients died of relapsed lymphoma a few months after transplant, 17 of the 20 patients (85 percent) are currently alive and in remission. In addition, the underlying HIV infection did not worsen as a result of the transplant and associated treatments. “The results of this study are significant because, despite the use of effective antiviral drugs such as HAART, lymphoma is still a major cause of suffering and death in HIV-infected individuals. It’s important to know that stem cell transplant is an available and highly successful treatment option for these patients,?said Amrita Krishnan, M.D., a staff physician at the City of Hope Cancer Center and l ead author of the study.
'"/>

Source:American Society of Hematology


Related biology news :

1. Novel Enzyme Shows Potential As An Anti-HIV Target
2. Potential treatments for neurofibromatosis
3. Stem Cell Research Shows Potential for Replacing Tissue Damaged in Heart Attacks
4. Potential Drug Target For Treating Cocaine Abuse Found
5. Potential vaccine developed for deadly leishmaniasis disease
6. Potential heart benefit found in stem cells
7. New Treatment Rivals Chemotherapy For Lymphoma, Study Finds
8. Measuring hormone cuts antibiotic use in half in pneumonia patients
9. Doctors closer to using gene analysis to help trauma patients
10. Research shows smoking adds a decade to reproductive age of IVF patients
11. Renewed hope for Parkinsons patients

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/2/2017)... 2017 Australian stem cell and regenerative medicine ... signed an agreement with the Monash Lung Biology Network, ... Institute and Department of Pharmacology at Monash University, ... study to support the use of Cymerus™ mesenchymal stem ... Asthma is a chronic, long term lung condition ...
(Date:2/28/2017)... 27. Februar 2017  EyeLock LLC, ein marktführendes Unternehmen ... erstklassige biometrische Lösung zur Iris-Erkennung auf der ... LTE auf dem Mobile World Congress 2017 ... in Halle 3, Stand 3E10, vorstellen. ... Qualcomm Haven™ – eine Kombination aus Hardware, ...
(Date:2/22/2017)... -- With the biometrics market to exceed $10 ... that innovative and agile startups must incorporate into ... changing competitive landscape: multifactor authentication (MFA), point-of-sale (PoS), ... "Companies can no longer afford to cut corners ... Pavlakis , Industry Analyst at ABI Research. "Pairing ...
Breaking Biology News(10 mins):
(Date:3/22/2017)... 22, 2017 Oramed Pharmaceuticals Inc. (NASDAQ: ... www.oramed.com ), a clinical-stage pharmaceutical company ... systems, announced today that Dr. Miriam Kidron ... presentation titled, "Oral Insulin for Diabetes Treatment: Bypassing ... Institute,s Oligonucleotide and Peptide Therapeutics (OPT) Boston Conference in ...
(Date:3/22/2017)... , March 22, 2017 The ... states a research report by Transparency Market Research (TMR). ... Amgen Inc., and AbbVie Inc., accounted for a share ... prominent players in this market are focusing aggressively on ... portfolio, which is likely to lead to market consolidation ...
(Date:3/22/2017)... TORONTO , March 22, 2017 /PRNewswire/ - ... Therapeutics (the "Company" or "Propellon"), a start-up created ... WDR5-targeted anti-cancer therapeutics. FACIT,s investment, combined with non-dilutive ... lead program. The seed funding enables Propellon to ... position the Company for financing and/or entering a ...
(Date:3/22/2017)... March 22, 2017   VWR ... of product and service solutions to laboratory ... has acquired EPL Archives, Inc., an international ... the entire regulated product research, development and ... storage and ancillary services. EPL Archives is ...
Breaking Biology Technology: